-
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2016;215:87.e1-87.e17. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH.
Am J Obstet Gynecol 2016;214:619.e1-619.e17. pdf -
Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:584-90. pdf -
Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
Fadigas C, Peeva G, Mendez O, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:191-7. pdf -
Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
Bakalis S, Peeva G, Gonzalez R, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:446-51. pdf -
Prediction of small-for-gestational-age neonates: maternal biochemical markers at 30-34 weeks.
Bakalis S, Gallo DM, Mendez O, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015:46:208-15. pdf -
Prediction of small for gestational age neonates: Screening by maternal serum biochemical markers at 19-24 weeks.
Lesmes C, Gallo DM, Gonzalez R, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:341-9. pdf -
Prediction of small for gestational age neonates: screening by biophysical and biochemical markers at 19-24 weeks.
Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:437-45. pdf -
Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;35:240-8. pdf -
Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;36:9-17. pdf -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks.
Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH.
Am J Obstet Gynecol 2009;200:508.1-6. -
First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstet Gynecol 2008;112:1082-90. -
Sonographic measurement of cervical length and fetal fibronectin testing in threatened preterm labor.
Tsoi E, Akmal S, Geerts L, Jeffery B, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:368-72. -
ADAM12-s in coelomic fluid and maternal serum in early pregnancy.
Makrydimas G, Sotiriadis A, Spencer K, Cowans NJ, Nicolaides KH.
Prenat Diagn 2006;26:1197-200. -
Cervicovaginal fibronectin and cervical length at 23 weeks of gestation: relative risk of early preterm delivery.
Heath VC, Daskalakis G, Zagaliki A, Carvalho M, Nicolaides KH.
BJOG 2000;107:1276-81.